National
Meet the trans editor covering Major League Baseball
Bobbie Dittmeier combines dual passions for sports, journalism
Bobbie Dittmeier (Photo courtesy of Dittmeier)
A day at the office at MLB.com for Bobbie Dittmeier is just about the same for her as it is for other editors working to produce news stories on developments in Major League Baseball.
Upon coming to the New York office, she’ll speak with the copy chief about potential articles for the day with other editors, who will then assign the stories to reporters.
“We have a lot of stories coming in everyday,” Dittmeier says. “We have 30 different reporters plus other columnists, part-timers and interns. We have a lot of writers for our staff. We cover all 30 teams full time. So, there’s a lot of copy that comes into the desk every day.”
FIND MORE OF THE WASHINGTON BLADE SPORTS ISSUE HERE.
The big news in recent weeks? The biogenesis investigation, which has led to the suspension of several players, including New York Yankees third baseman Alex Rodriguez.
“Waiting for the news on Alex Rodriguez is like waiting for your wife to go into labor,” she says. “You got the bags packed and the cars gassed, and you’re just going about your regular routine waiting for the pager to go off. And knowing that when the pager does go off that the next 12 to 18 hours is going to be crazy.”
But Dittmeier, who spoke to the Washington Blade earlier this month, is unique among other editors and baseball enthusiasts working at MLB.com: She’s transgender and the only openly LGBT person on staff at the site.
Dittmeier says being the only openly transgender person on staff hasn’t been an issue on the job, which she attributes to changing attitudes over time and her own job performance.
“I think the most significant part of it is that I have a lot of experience and I do good work, if I may say so myself,” Dittmeier says. “And I think that the people I work for value that. They certainly didn’t want to throw me out of the office for being transgender.”
One exception to the acceptance she’s found was what Dittmeier calls a “blip” among two individuals upon her announcement she would transition. Reluctant to go into detail, she characterizes it as more of a misunderstanding and says neither of those people works at MLB.com any longer.
In 2007, after working for MLB.com for six years, Dittmeier announced she would transition from male to female. She had already married and had a child. And it wasn’t her first attempt; she made an earlier attempt at transitioning in the 1990s.
“It was really only after I had been at MLB for a number of years that I felt comfortable and confident enough that transition wasn’t going to put me on the street,” Dittmeier said. “So, I felt I had job security, I knew the people I worked for, I knew that they knew I do a good job, that I’m good at what I do, so I didn’t think it would be that much of an issue. So, I worked toward it for a couple years, starting probably around 2005, and then finally culminating in coming out at work in 2007.”
Dittmeier says she “always kind of felt something different” about her when she was growing up in Long Island during her youth, but wasn’t at the time able to identify it because of a lack of information.
“I kind of figured it out in my teens, but you don’t act upon it because, again, it was a different time,” Dittmeier says. “You didn’t know if you were going to be ostracized from your family, you didn’t have the resources, you certainly didn’t have the Internet. Going to a shrink was really frowned upon. You certainly didn’t talk about these things with your parents.”
At the same time growing up, Dittmeier was an avid enthusiast of all things baseball and newsprint. After school, she would read the sports columns in Newsday, a Pulitzer Prize-winning paper that was distributed in her hometown.
“And it was an afternoon paper, so it would come to the house during the day, and I would come home from school, and the first thing I would do before I went out to play ball was I would make myself a sandwich and I would read the newspaper, then I would go out and play ball,” Dittmeier says. “So, I always loved journalism. I always loved writing.”
Dittmeier started in the business of sports writing as a beat reporter covering hockey and horseracing, mostly in Westchester County just outside of New York, and then in Albany for a number of years. She wanted to get involved in baseball, but didn’t have the opportunity. Landing the job at MLB.com 12 years ago made that dream come true.
One recent big news story hit close to home. In July, Major League Baseball announced that it had adopted an employment non-discrimination policy prohibiting discrimination based on sexual orientation. Dittmeier says she didn’t cover the story personally, although MLB.com had a reporter, Paul Hagen, covering it.
“Personally, it doesn’t impact me at all, I don’t think,” Dittmeier says. “But I’m certainly glad to see Major League Baseball take it to that level and respond like that. I think that’s more for clubhouses, players, the teams more than me.”
The policy doesn’t cover gender identity, but Dittmeier isn’t discouraged. New York City, where she lives and works, has employment non-discrimination protections based on gender identity.
“It’s not troubling for me personally,” Dittmeier says. “It would be nice if they took a look at that. But again, for me, personally I don’t think that I’m at any kind of risk as long as I’m doing my job well. If I don’t do my job well, then I’m subject to changes just like everybody else. If it’s not there, it would be nice if they would include it, I’m sure.”
Asked about the prevalence of gay players in Major League Baseball, Dittmeier insists there are such players who haven’t made their sexual orientation or gender identity public yet.
“There has to be,” Dittmeier says. “I remember having a debate with a hockey coach years and years ago who insisted there were no gay players anywhere in professional hockey, and I told him I thought that was ridiculous. If the number is 10 percent of the population is gay, then there has to be.”
But even with the MLB’s non-discrimination policy on sexual orientation in place, Dittmeier says it would take a player with exceptional skills to come out as gay — more talent than what an average baseball player normally has.
“If you are hitting 300 and you’re a perennial all-star, and you happen to be [gay, bi or trans], your chances of successfully coming out are pretty good,” Dittmeier says. “If you’re going up and down between Triple-A and the major leagues, that’s a tough one, because if it comes down to a decision between that player and someone else as to whether they’re going to make the roster, then you have to worry about someone, consciously or unconsciously, choosing the other player because of your sexual orientation.”
Although he’s not a baseball player, the most notable coming out of a gay athlete this year was former Washington Wizards center Jason Collins. It’s his status as a veteran that Dittmeier says made that coming out possible.
“He’s 34 years old,” Dittmeier says. “He’s a good ball player at this point in his career. If, for some reason, he discontinues to play, he’s had a pretty good career. So he doesn’t have very much to lose. When he was 23, 24, 25 years old, he certainly had a lot more to lose than he does now. I think security is really, really important.”
Dittmeier says she’s seen attitudes change positively in recent decades, and expects those to change even further as time progresses — particularly for transgender people like herself.
“I know most people don’t know someone who is transgender, but certainly most people know someone else who’s LGBT,” Dittmeier says. “And 20 years ago, I don’t think you could say that. Once you know someone, either someone in your life or someone you get to know, someone they work with or whatever, they understand it better. I guess that’s probably like with anything in life.”
CORRECTIONS: An earlier version of this article misspelled the name of MLB.com reporter Paul Hagen. It was also incorrect about the position that Alex Rodriguez currently plays and Dittmeier’s hometown. The article has also been updated to clarify that New York City has transgender non-discrimination protections. The Blade regrets the errors.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
‘Dogs of Venice’ looks at love lost and rediscovered
A Wider Bridge to close
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
Rehoboth’s Blue Moon is for sale but owners aim to keep it in gay-friendly hands
Comings & Goings
LGBTQ Democrats say they’re ready to fight to win in 2026
Brian Footer suspends campaign for Ward 1 D.C. Council seat
Lighting candles in a time of exhaustion
Why queer spaces often fail South Asian women
